ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.

Breelyn A Wilky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.